• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Allergan closes $2.48B Zeltiq acquisition

April 28, 2017 By Sarah Faulkner

Allergan CoolSculpting SystemAllergan (NYSE:AGN) said today that it closed its $2.48 billion acquisition of Zeltiq Aesthetics Inc. (NSDQ:ZLTQ) and its portfolio of body-contouring products.

Zeltiq’s FDA-approved CoolSculpting system uses a cooling mechanism to reduce the appearance of fat which has not responded to diet or exercise, without disturbing surrounding tissue.

According to the deal, Allergan agreed to pay $56.50 per Zeltiq share. Zeltiq shareholders approved the agreement during its stockholder meeting yesterday.

Allergan CEO Brent Saunders has been eager to land a deal since its $160 billion merger with Pfizer collapsed last year. Saunders has previously said the company will continue to look for deals and it expects that its injection Kybella, which is used to diminish fat under the chin, will do well in 2017.

“We are thrilled to complete the acquisition of Zeltiq, which immediately expands our world-class global aesthetic business into the highly-complementary and fast-growing body contouring segment,” Allergan chief commercial officer Bill Meury said in prepared remarks. “CoolSculpting gives Allergan the most comprehensive and dynamic portfolio of products for plastic surgeons, dermatologists and other aesthetic providers across the globe.”

“In my practice, there is growing demand from patients for less invasive treatments for bothersome pockets of fat on their body. CoolSculpting addresses that need, and we continue to see strong demand for the procedures because of its reliable ability to remove fat non-invasively,” Dr. Grant Stevens, from the University of South California School of Medicine, added. “I am excited to see the CoolSculpting technology now being added to Allergan’s broad aesthetic product offering, and eager to see how they will expand the opportunity for body contouring.”

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Zeltiq Aesthetics

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS